Literature DB >> 1702176

Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implications in peptide delivery from nonoral routes.

A Yamamoto1, E Hayakawa, V H Lee.   

Abstract

The objective of this study was to determine (a) the rate of hydrolysis of insulin and proinsulin in homogenates of various non-oral absorptive mucosae relative to the ileal mucosa, and (b) the inhibitory effect of various protease inhibitors on the degradation of these peptides. Overall, insulin was somewhat more susceptible to hydrolysis than proinsulin in all mucosal homogenates. Proteolytic activity was highest in the nasal and rectal homogenates, followed by the ileal, vaginal, conjunctival and buccal homogenates in that order. The rate of insulin and proinsulin proteolysis differed by a factor of about 6 to 7 between the least and the most proteolytically active mucosa. A 5-fold maximum reduction in proteolytic rate was seen in the presence of Na glycocholate, aprotinin and p-chloromercuriphenyl-sulfonic acid (PCMPS). The rank order of effectiveness was Na glycocholate (1%) greater than aprotinin greater than PCMPS in all but the conjunctival and vaginal homogenates. Extrapolating the above in vitro findings to in vivo, both insulin and proinsulin are expected to be degraded to varying degrees during absorption across the various mucosae. Absorption may therefore be enhanced in the presence of protease inhibitors such as aprotinin, PCMPS, or Na glycocholate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702176     DOI: 10.1016/0024-3205(90)90492-a

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Influence of absorption promoters on pulmonary insulin bioactivity.

Authors:  T Mahesh Kumar; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

2.  Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats.

Authors:  T Uchiyama; A Kotani; H Tatsumi; T Kishida; A Okamoto; N Okada; M Murakami; T Fujita; Y Fujiwara; Y Kiso; S Muranishi; A Yamamoto
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 3.  Enhancing the buccal mucosal delivery of peptide and protein therapeutics.

Authors:  Thiago Caon; Liang Jin; Cláudia M O Simões; Raymond S Norton; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-08-29       Impact factor: 4.200

4.  Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats.

Authors:  A Yamamoto; T Taniguchi; K Rikyuu; T Tsuji; T Fujita; M Murakami; S Muranishi
Journal:  Pharm Res       Date:  1994-10       Impact factor: 4.200

5.  Insulin-degrading enzyme in a human colon adenocarcinoma cell line (Caco-2).

Authors:  J P Bai; M J Hsu; W T Shier
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

6.  Conjunctival penetration of insulin and peptide drugs in the albino rabbit.

Authors:  E Hayakawa; D S Chien; K Inagaki; A Yamamoto; W Wang; V H Lee
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

7.  Stability of acyl derivatives of insulin in the small intestine: relative importance of insulin association characteristics in aqueous solution.

Authors:  H Asada; T Douen; Y Mizokoshi; T Fujita; M Murakami; A Yamamoto; S Muranishi
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

8.  Improvement of the pulmonary absorption of (Asu1,7)-eel calcitonin by various protease inhibitors in rats.

Authors:  T Morita; A Yamamoto; Y Takakura; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

9.  Transepithelial transport of insulin: I. Insulin degradation by insulin-degrading enzyme in small intestinal epithelium.

Authors:  J P Bai; L L Chang
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.